PT2710033T - Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes - Google Patents

Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes

Info

Publication number
PT2710033T
PT2710033T PT127859296T PT12785929T PT2710033T PT 2710033 T PT2710033 T PT 2710033T PT 127859296 T PT127859296 T PT 127859296T PT 12785929 T PT12785929 T PT 12785929T PT 2710033 T PT2710033 T PT 2710033T
Authority
PT
Portugal
Prior art keywords
methods
immunodeficiency virus
human immunodeficiency
neutralizing antibodies
virus neutralizing
Prior art date
Application number
PT127859296T
Other languages
English (en)
Original Assignee
Univ Rockefeller
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, California Inst Of Techn filed Critical Univ Rockefeller
Publication of PT2710033T publication Critical patent/PT2710033T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
PT127859296T 2011-05-17 2012-05-17 Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes PT2710033T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161486960P 2011-05-17 2011-05-17

Publications (1)

Publication Number Publication Date
PT2710033T true PT2710033T (pt) 2021-03-11

Family

ID=47177348

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127859296T PT2710033T (pt) 2011-05-17 2012-05-17 Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes

Country Status (20)

Country Link
US (5) US9783594B2 (pt)
EP (2) EP3865507A1 (pt)
JP (5) JP6323718B2 (pt)
CN (4) CN106432484B (pt)
AU (5) AU2012255266B2 (pt)
BR (1) BR112013029550A2 (pt)
CA (1) CA2836468C (pt)
CY (1) CY1124043T1 (pt)
DK (1) DK2710033T3 (pt)
EA (2) EA201990685A1 (pt)
ES (1) ES2895523T3 (pt)
HR (1) HRP20210375T1 (pt)
HU (1) HUE053545T2 (pt)
IL (4) IL295205B1 (pt)
LT (1) LT2710033T (pt)
MX (1) MX358099B (pt)
PL (1) PL2710033T3 (pt)
PT (1) PT2710033T (pt)
SI (1) SI2710033T1 (pt)
WO (1) WO2012158948A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029550A2 (pt) * 2011-05-17 2022-04-19 California Inst Of Techn Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
EP2736532B1 (en) 2011-07-25 2018-05-16 California Institute of Technology Compositions and methods for improving potency and breadth or hiv antibodies
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
WO2013192589A1 (en) 2012-06-21 2013-12-27 California Institute Of Technology Antibodies targeting hiv escape mutants
US10308707B2 (en) * 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015117008A2 (en) 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
KR20230104759A (ko) * 2014-09-30 2023-07-10 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
WO2016062988A1 (en) * 2014-10-22 2016-04-28 Crescendo Biologics Limited Vh scaffold
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
HUE049081T2 (hu) 2015-03-20 2020-09-28 The United States Of America As GP120 elleni neutralizáló antitestek és alkalmazásuk
CR20180288A (es) * 2015-10-25 2018-09-11 Us Health Proteínas de union triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
CA3016352A1 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
JP7195929B2 (ja) 2016-04-13 2022-12-26 サノフイ 三重特異性および／または三価結合タンパク質
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
US11161895B2 (en) 2016-10-03 2021-11-02 Duke University Methods to identify immunogens by targeting improbable mutations
US11149082B2 (en) 2016-10-17 2021-10-19 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
CN116948018A (zh) * 2016-12-27 2023-10-27 洛克菲勒大学 广谱中和抗hiv-1抗体及其使用方法
US10875890B2 (en) * 2017-03-14 2020-12-29 Oregon State University Peptide inhibitors targeting the Neisseria gonorrhoeae pivotal anaerobic respiration factor AniA
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
MX2020004129A (es) 2017-10-10 2020-08-20 Sanofi Sa Anticuerpos anti-cd38 y metodos de uso.
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
WO2019173802A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Anti-hiv antibodies
CN110305219B (zh) * 2018-03-27 2021-05-04 清华大学 一种包含嵌合抗原受体（car）修饰的t细胞在制备细胞药物中的用途
CA3101680A1 (en) * 2018-05-25 2019-11-28 Temple University-Of The Commonwealth System Of Higher Education Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
WO2020056145A1 (en) * 2018-09-14 2020-03-19 The Rockefeller University Anti-hiv antibody 10-1074 variants
US11530268B2 (en) 2018-10-09 2022-12-20 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TW202146463A (zh) * 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
MX2023002194A (es) 2020-08-25 2023-03-03 Gilead Sciences Inc Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso.
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024530527A (ja) * 2021-08-13 2024-08-21 アブウィズ バイオ，インコーポレイテッド タンパク質及び抗体のヒト化、親和性成熟、及び最適化のための方法
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
EP4440702A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AU2022425312A1 (en) 2021-12-31 2024-07-18 Beijing Solobio Genetechnology Co., Ltd. Chimeric antigen receptor t cells targeting hiv-infected cells
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus
WO2023192827A1 (en) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IL89567A0 (en) 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5445960A (en) * 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ATE175997T1 (de) 1991-08-10 1999-02-15 Medical Res Council Behandlung von zellpopulationen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0690132T3 (da) 1993-03-11 2004-04-13 Chemo Sero Therapeut Res Inst Monoklonalt anti-HIV-antistof
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
JPH08510246A (ja) * 1993-05-07 1996-10-29 アクゾ・ノベル・エヌ・ベー Ｈｉｖ免疫原性複合体
EP0794792A1 (en) 1994-12-02 1997-09-17 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002068649A2 (en) * 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
AU2002365978A1 (en) 2001-11-19 2003-06-10 Applied Molecular Evolution, Inc. Tumor specific monoclonal antibodies
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US20030232387A1 (en) 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US8333971B2 (en) * 2006-05-15 2012-12-18 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
US7824681B2 (en) * 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
JP4895727B2 (ja) * 2006-08-28 2012-03-14 シスメックス株式会社 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法
TWI595005B (zh) * 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2098536A1 (en) * 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
ES2828627T3 (es) 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
BRPI0914916A2 (pt) 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
JP5804521B2 (ja) 2009-05-29 2015-11-04 モルフォシス・アー・ゲー コレクション及びその使用方法
IN2012DN01328A (pt) 2009-08-13 2015-06-05 Crucell Holland Bv
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) * 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
BR112013029550A2 (pt) * 2011-05-17 2022-04-19 California Inst Of Techn Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
EP2736532B1 (en) * 2011-07-25 2018-05-16 California Institute of Technology Compositions and methods for improving potency and breadth or hiv antibodies
US9493549B2 (en) * 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
PL2908912T3 (pl) * 2012-10-18 2021-05-17 The Rockefeller University Szeroko neutralizujące przeciwciała anty-hiv
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers

Also Published As

Publication number Publication date
HRP20210375T1 (hr) 2021-07-09
SI2710033T1 (sl) 2021-05-31
CN116948019A (zh) 2023-10-27
EP3865507A1 (en) 2021-08-18
AU2012255266A1 (en) 2013-12-19
IL229469A0 (en) 2014-01-30
JP2024001150A (ja) 2024-01-09
AU2019200972A1 (en) 2019-02-28
HUE053545T2 (hu) 2021-07-28
IL295205A (en) 2022-10-01
US9783594B2 (en) 2017-10-10
EP2710033A1 (en) 2014-03-26
EP2710033A4 (en) 2015-04-22
DK2710033T3 (da) 2021-03-08
US20210230254A1 (en) 2021-07-29
US20180079800A1 (en) 2018-03-22
JP2014516527A (ja) 2014-07-17
CN103797029A (zh) 2014-05-14
CN106432484A (zh) 2017-02-22
US20230365661A1 (en) 2023-11-16
EP2710033B1 (en) 2021-01-20
JP2020202827A (ja) 2020-12-24
AU2020201993A1 (en) 2020-04-09
JP2022115945A (ja) 2022-08-09
JP7076721B2 (ja) 2022-05-30
CY1124043T1 (el) 2022-05-27
CN112225798B (zh) 2023-07-18
US11634478B2 (en) 2023-04-25
IL313030A (en) 2024-07-01
AU2020201993B2 (en) 2022-03-31
IL295205B1 (en) 2024-07-01
BR112013029550A2 (pt) 2022-04-19
MX2013013360A (es) 2014-09-22
EA201391713A1 (ru) 2014-07-30
JP2018161126A (ja) 2018-10-18
MX358099B (es) 2018-08-06
CN103797029B (zh) 2016-08-17
CN112225798A (zh) 2021-01-15
CA2836468C (en) 2021-05-04
AU2012255266B2 (en) 2017-05-25
AU2017204563A1 (en) 2017-07-27
US20240254206A1 (en) 2024-08-01
JP6720242B2 (ja) 2020-07-08
PL2710033T3 (pl) 2021-10-25
EA032929B1 (ru) 2019-08-30
AU2019200972B2 (en) 2020-04-16
EA201990685A1 (ru) 2019-12-30
CA2836468A1 (en) 2012-11-22
WO2012158948A1 (en) 2012-11-22
LT2710033T (lt) 2021-06-10
IL276182B (en) 2022-09-01
US12071470B2 (en) 2024-08-27
US10889633B2 (en) 2021-01-12
US20140328862A1 (en) 2014-11-06
JP7368812B2 (ja) 2023-10-25
ES2895523T3 (es) 2022-02-21
IL276182A (en) 2020-09-30
AU2017204563B2 (en) 2018-11-22
JP6323718B2 (ja) 2018-05-16
IL229469B (en) 2020-08-31
AU2022204340A1 (en) 2022-07-14
CN106432484B (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
IL276182A (en) Neutralizing antibodies against the human immunodeficiency virus and methods of using them
HK1255608A1 (zh) 抗htra1抗體及使用方法
ZA201404077B (en) Neutralizing antibodies to hiv -1 and their use
ZA201403264B (en) Neutralizing gp41 antibodies and their use
HK1202123A1 (en) Human antibodies to fel d1 and methods of use thereof fel d1
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
EP2663330A4 (en) ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE
HK1206249A1 (en) Human autotaxin antibodies and methods of use (autotaxin)
EP2694533A4 (en) METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
ZA201304490B (en) Neutralizing human anti-v3 monoclonal antibodies and use thereof for the production of vaccine against hiv